Have questions about EYLEA, Diabetic Macular Edema (DME), or Diabetic Retinopathy (DR) in DME? We have answers.
Both DME and DR are serious eye conditions caused by diabetes. DME is a complication of DR. DR happens when too much blood sugar (glucose) damages the blood vessels in the retina. As a result, the retina does not get enough blood and nutrients, and blood vessels can leak blood into the retina. DME happens when the damaged blood vessels leak fluid into the macula (the part of the retina responsible for sharp central vision).
In the United States, more than 1 in 4 people 40 years of age and older with diabetes had a serious eye condition (such as DME) that may cause vision loss between 2005 and 2008. DR is the leading cause of vision loss in working-age adults.
DME may cause blurriness or waviness in the center of vision, the appearance of blind spots or patches in the field of vision, and colors to look dull. These symptoms may affect the ability to read, write, drive, and recognize faces.
EYLEA is a prescription medicine approved by the Food and Drug Administration for the treatment of DME and DR in DME, as well as Wet Age-related Macular Degeneration (Wet AMD) and Macular Edema following Retinal Vein Occlusion (RVO). You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Your eye doctor will diagnose you with a retina condition that may be treated with EYLEA. A retina specialist is an ophthalmologist specially trained to diagnose and treat retina conditions such as DME and DR in DME.
EYLEA works by blocking vascular endothelial growth factor (VEGF), a protein made by the blood vessels. At high levels, VEGF can cause abnormal blood vessels to grow in the eye and leak fluid (the part of the retina responsible for sharp central vision). Blocking VEGF helps reduce the fluid leaking into the macula.
There is no cure for these eye conditions. Treatment with EYLEA, however, has been shown to help maintain or improve vision in many people with DME or DR in DME. In two clinical studies, 862 people with DME received injections of EYLEA (2mg) either once every 8 weeks after 5 initial monthly doses or once every 4 weeks or laser treatment.
The most common side effects reported in people receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.
Anyone who has an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept, should not use EYLEA.
Your eye doctor will examine, wash, and numb your eye and then administer EYLEA as an injection into the eye. Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA. Talk to your eye doctor if you experience any side effects, including eye pain, redness of the eye, light sensitivity, or blurring of vision.
It is important not to miss a scheduled injection of EYLEA. If you do, be sure to make a new appointment as soon as possible.
Each person responds to treatment with EYLEA differently, including any effects of treatment. Talk with your eye doctor about your individual response and expectations over time—he or she will monitor your progress at every step of your treatment plan.
EYLEA4U® is a support program that may be able to help. Either you or your eye doctor's office can call 1-855-EYLEA4U (1-855-395-3248) Monday through Friday 9 AM to 8 PM Eastern Time to get you started.
When your eye doctor prescribes EYLEA, whether you have private or government insurance (Medicare/Medicaid) or have no insurance coverage, you can be confident that EYLEA4U is here to help. And we can conduct a Benefits Investigation with your insurer to determine your coverage for EYLEA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with:
The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.